Skip to content

In Vivo Investigation of Novel Nano-vesicles of Salbutamol Sulphate

Novel Nano-vesicles of Salbutamol Sulphate in Metered Dose Inhalers: Formulation, Characterization, In Vitro and In Vivo Evaluation

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03059017
Enrollment
20
Registered
2017-02-23
Start date
2017-02-05
Completion date
2017-02-05
Last updated
2017-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug Effect, Pulmonary Disease

Brief summary

The relative bioavailability of different salbutamol sulphate inhaler formulations will be studied in healthy male subjects according to the ethical regulations of World Medical Association Declaration of Helsinki (1996) after the approval of the ethical committee, Faculty of Pharmacy, The British University in Egypt.

Detailed description

In this study, 20 healthy, non smoking, adult male volunteers (age: 30-45 years, weight: 65-80 kg) will carry out screening procedures which include instruction and practice with the placebo metered dose inhaler devices that will be used in the study. In addition, all subjects were fully informed in writing of the objectives and implications of the trial. No subject will be considered for the study if developed any symptoms of allergic disorders. Subjects will follow a normal diet and will not receive any other medications. Volunteers will be divided into two groups; each group contained 10 volunteers who will receive one formula of the selected formulae. Each volunteer will inhale eight puffs (4 puffs at -5 min & 4 puffs at 0 min) which are equivalent to 0.8 mg of salbutamol sulphate . To inhale through metered dose inhalers, volunteers will be trained to exhale slowly to their residual volume (as far as comfortable), put the inhaler into their mouth and seal their lips round the mouth piece. Then they will be instructed to take a slow deep inspiration to their total lung capacity over approximately 5-10 seconds. At the end of each inhalation, they will hold their breath for 10 seconds and then breathe normally (Ball et al, 2002) . Three milliliters of blood will be withdrawn at 0, 0.5, 1, 2, 3, 4, 5 and 6 h after administration. The blood will be heparinized immediately and centrifuged at 3000 rpm for 10 minutes. The plasma samples will be stored at freeze temperature until analysis. Two different formulae will be compared during the first six hours following administration. The maximum plasma concentration (Cmax), the time required to reach maximum plasma concentration (Tmax) and the area under plasma concentration time curve (AUC) will be calculated using validated Excel software.

Interventions

salbutamol sulphate packaged as aerosol

DRUGNiosomes

Niosomes

Sponsors

British University In Egypt
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Volunteers will be divided into two groups; each group contained 10 volunteers who will receive one formula of the selected formulae.

Eligibility

Sex/Gender
MALE
Age
30 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy

Exclusion criteria

* Chronic disease * Smoking * Hospitalization

Design outcomes

Primary

MeasureTime frameDescription
The maximum plasma concentration (Cmax)Twenty Four HoursThe maximum concentration of Salbutamol Sulphate in human blood after time intervals 0, 30, 1,2, 3,4 , 5 & 6 hs will be calculated using validated using Excel software.

Secondary

MeasureTime frameDescription
The time required to reach maximum plasma (Tmax)Twenty Four HoursTime taken for Salbutamol Sulphate to reach its maximum concentration in human blood & will be calculated using validated using Excel software

Other

MeasureTime frameDescription
The area under plasma concentration time curve (AUC)Twenty Four HoursThe integral in a plot of concentration of Salbutamol Sulphate in blood plasma against time.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026